X

Clinical Trials

Contact Us

EA5163 **Upcoming Closure to Accrual 3/1/24 @ 4pm cst** (Only patients who have signed a consent to participate on or before 4:00 PM (cst) February 23, 2024 and have completed their registration by 4:00 PM (cst) March 1, 2024 will be accepted)

Study Number: EA5163 **Upcoming Closure to Accrual 3/1/24 @ 4pm cst** (Only patients who have signed a consent to participate on or before 4:00 PM (cst) February 23, 2024 and have completed their registration by 4:00 PM (cst) March 1, 2024 will be accepted)

This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as pemetrexed and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving first-line pembrolizumab followed by pemetrexed and carboplatin with or without pembrolizumab works better in treating patients with non-squamous non-small cell cancer.

Available Sites
  • Missouri Baptist Medical Center
  • Missouri Baptist Outpatient Center – Sunset Hills
  • Missouri Baptist Sullivan Hospital
  • Sainte Genevieve County Memorial Hospital
  • Parkland Health Center - Farmington
Contact Person(s)
  • Patricia Kulla, 314-996-4617

View More Information - This link will take you to clinicaltrials.gov for specific study information including eligibility criteria. A full list of participating institutions can also be found on this page.